title: Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis.
abstract: Tumor necrosis factor (TNF)-targeted therapies are increasingly used to treat a variety of inflammatory and autoimmune diseases. They are now used worldwide, and this class of medication has revolutionized the treatment of these diseases and the quality of life for patients but it also poses risk of developing various side effects including infections, exacerbation of some neurological manifestations, cutaneous lesions or induces antibody production. Renal complications are uncommon and poorly recognized. This report describes a probable case of infliximab-induced focal segmental glomerulosclerosis clinically presented as a severe nephrotic syndrome in a patient with ulcerative colitis.
authors.affiliation: Department of Gastroenterology, IBD and Nutrition Support, Beaujon Hospital, Paris VII University, Clichy, France; Gr. T Popa University of Medicine and Pharmacy Iasi, Romania.
authors.forename: Gabriela
authors.initials: G
authors.lastname: Dumitrescu
authors.affiliation: Department of Nephrology, Tenon Hospital, Paris VI University, Paris, France.
authors.forename: Karine
authors.initials: K
authors.lastname: Dahan
authors.affiliation: Department of Gastroenterology, IBD and Nutrition Support, Beaujon Hospital, Paris VII University, Clichy, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Treton
authors.affiliation: Department of Gastroenterology, IBD and Nutrition Support, Beaujon Hospital, Paris VII University, Clichy, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Corcos
authors.affiliation: Department of Gastroenterology, IBD and Nutrition Support, Beaujon Hospital, Paris VII University, Clichy, France.
authors.forename: Yoram
authors.initials: Y
authors.lastname: Bouhnik
authors.affiliation: Department of Gastroenterology, IBD and Nutrition Support, Beaujon Hospital, Paris VII University, Clichy, France. ac.stefanescu@gmail.com.
authors.forename: Carmen
authors.initials: C
authors.lastname: Stefanescu
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D057915:Drug Substitution; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D005923:Glomerulosclerosis, Focal Segmental / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D000069285:Infliximab / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab